Boston Scientific Corp.
BSX
$0.00
-1.20%
Boston Scientific Corp. is a leading global manufacturer of less invasive medical devices used in various therapeutic areas. It is defined by its diversified portfolio and long-term innovation track record in the medical device industry.
BSX
Boston Scientific Corp.
$0.00
Related headlines
Investment Opinion: Should I buy BSX Today?
Based on a synthesis of the data, the objective assessment is a Buy for investors with a medium-to-long-term horizon and tolerance for volatility. This rating balances the unanimous 'Buy' analyst consensus and attractive forward P/E of 16.1x against the severe technical breakdown. The current price near the 52-week low presents a potential entry point, but investors must be prepared for near-term volatility as sentiment recovers. The recommendation is contingent on belief in the company's diversified portfolio and long-term innovation track record to overcome recent setbacks.
Sign up to view all
BSX 12-Month Price Forecast
The data suggests a cautiously optimistic neutral stance. The severe sell-off appears overdone relative to the company's financial strength, creating a potential opportunity. However, the technical damage and high trailing valuation warrant caution, making a swift V-shaped recovery unlikely. The base case of a gradual grind higher is most probable.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific Corp.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
16 analysts
Implied Upside
—
vs. current price
Analyst Count
16
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analysts maintain a bullish consensus on Boston Scientific, with recent ratings from 10 major firms all being 'Buy' or equivalent (e.g., Overweight). The coverage is substantial, with 16 analysts providing estimates. The consensus estimates for the company are an average EPS of $5.61 on average revenue of $33.07 billion. No specific consensus price target data is provided in the inputs, but the unanimous recent 'Buy' ratings from major institutions indicate strong analyst conviction despite the recent stock price weakness.
Bulls vs Bears: BSX Investment Factors
BSX presents a classic conflict between strong fundamentals and broken technicals/sentiment. The company's financial health, growth, and analyst support are compelling, but the stock has been crushed by a specific negative catalyst and is trading on fear. The current price appears to discount significant pessimism.
Bullish
- Strong Revenue Growth: Q4 revenue grew 15.9% YoY, demonstrating robust underlying business performance.
- Solid Profitability & Cash Flow: TTM net margin of 14.4% and strong FCF of $3.63B provide financial flexibility.
- Attractive Forward Valuation: Forward P/E of 16.1x and PEG ratio of 0.88 suggest potential undervaluation.
- Unanimous Analyst Conviction: 10 recent analyst ratings are all 'Buy', indicating strong professional confidence.
Bearish
- Severe Price Collapse: Stock down ~35% in 6 months, underperforming S&P 500 by ~32%.
- Elevated Trailing Valuation: Trailing P/E of 48.9x and EV/EBITDA of 40.6x are very high.
- Negative Clinical Trial Catalyst: Recent 'underwhelming trial results' triggered the sharp sell-off.
- High Relative Valuation Multiples: P/S ratio of 7.0 and P/B of 5.8 are elevated for the sector.
BSX Technical Analysis
The stock's overall trend has been sharply negative over the past six months, with the price declining from approximately $100 in October 2025 to $62.75 as of March 31, 2026, representing a 34.8% drop. This downtrend accelerated significantly in the last quarter, with a 34.2% decline over three months and an 18.3% decline over one month, severely underperforming the broader market as indicated by the negative relative strength figures. Short-term performance has been exceptionally weak, with the stock falling 18.35% over the past month, compared to a 5.25% decline for the S&P 500. Over the last three months, the stock is down 34.19%, far worse than the S&P 500's 4.63% decline, highlighting significant underperformance. The current price of $62.75 is near the bottom of its 52-week range of $61.25 to $109.50, sitting just 2.4% above the 52-week low. This position, combined with a maximum drawdown of -41.97%, indicates the stock is in a deeply oversold technical condition.
Beta
0.70
0.70x market volatility
Max Drawdown
-42.7%
Largest decline past year
52-Week Range
$61-$110
Price range past year
Annual Return
-38.8%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | -18.7% | -3.7% |
| 3m | -35.0% | -4.1% |
| 6m | -36.3% | -2.1% |
| 1y | -38.8% | +16.1% |
| ytd | -34.5% | -3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Revenue growth remains strong, with Q4 2025 revenue of $5.29 billion representing a 15.9% year-over-year increase. Profitability metrics are solid, with a Q4 net margin of 12.6% and a trailing twelve-month net margin of 14.4%, supported by a gross margin of 69.0% and an operating margin of 19.8%. Financial health is reasonable, with a debt-to-equity ratio of 0.51 and a current ratio of 1.62, indicating adequate liquidity. The company generates substantial free cash flow, with TTM free cash flow of $3.63 billion, providing flexibility for operations and potential acquisitions. Operational efficiency is demonstrated by a Return on Equity (ROE) of 11.9% and a Return on Assets (ROA) of 6.0%. The company's asset turnover and interest coverage of 13.4x reflect effective use of its asset base and a comfortable ability to service its debt obligations.
Quarterly Revenue
$5.3B
2025-12
Revenue YoY Growth
+0.15%
YoY Comparison
Gross Margin
+0.74%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is elevated at 48.9x, while the forward P/E is a more reasonable 16.1x based on estimated EPS of $5.61. The PEG ratio of 0.88 suggests the stock may be undervalued relative to its expected earnings growth. Peer comparison data is not available in the provided inputs. Other valuation metrics include a Price-to-Sales (P/S) ratio of 7.03 and an EV/EBITDA of 40.6. The high trailing P/E and EV/EBITDA ratios reflect market concerns, potentially related to recent trial results, while the forward P/E and PEG ratio suggest a more attractive forward-looking valuation.
PE
48.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 37x~161x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
40.6x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is the erosion of investor confidence following the disappointing clinical trial results, as evidenced by the stock's 34% decline in three months. This event risk has materialized and may continue to weigh on the stock until the company demonstrates a clear path to regrowth or provides positive updates on its pipeline. Valuation risk remains high despite the drop; the trailing P/E of 48.9x is steep and suggests earnings must grow into the valuation. Furthermore, the stock's high P/S and P/B ratios indicate it is still priced for perfection relative to sales and assets, leaving it vulnerable to multiple compression if growth expectations moderate. Operational risks include the inherent uncertainties in medical device development and regulatory approvals, while market risk is highlighted by its significant underperformance versus the broader market despite a low beta of 0.7.
FAQ
Key risks include: 1) Sentiment & Clinical Risk: The stock crashed on 'underwhelming trial results,' and regaining investor confidence is uncertain. 2) Valuation Risk: Lofty trailing multiples (P/E 48.9x) require flawless execution. 3) Market Risk: The stock has severely underperformed the S&P 500 (down 34% vs. market's -4.6% over 3 months). 4) Operational Risk: Medical device development is fraught with regulatory and trial uncertainties.
The 12-month outlook is for a potential recovery, with a base case target range of $70-$85 (11%-36% upside from $62.75). This assumes the company meets the analyst consensus EPS of $5.61, justifying a forward P/E of 18-19x. The bull case ($90-$109) depends on a full sentiment reversal, while the bear case ($61-$68) involves retesting lows. The probability-weighted assessment suggests gradual appreciation is most likely.
BSX sends mixed valuation signals. It appears overvalued on a trailing basis with a P/E of 48.9x and EV/EBITDA of 40.6x. However, it looks potentially undervalued on a forward-looking basis, with a forward P/E of 16.1x and a PEG ratio of 0.88 (below 1.0). The sharp price decline has improved forward valuation metrics significantly, but high sales and book multiples (P/S 7.0, P/B 5.8) indicate the market still prices in premium growth.
BSX could be a good buy for investors with a long-term horizon and risk tolerance. The stock is deeply oversold, trading just 2.4% above its 52-week low, yet the company maintains strong 15.9% revenue growth and a 14.4% net margin. With all recent analyst ratings being 'Buy' and a forward P/E of 16.1x, the valuation appears reasonable for its growth profile, suggesting the market may have overreacted to recent trial news.
BSX is primarily suitable for long-term investment. The stock's severe technical damage and reliance on pipeline execution mean a recovery could take quarters or years, not weeks. Short-term traders face high volatility and negative momentum. Long-term investors can look through the current sentiment crisis to the company's solid fundamentals, diversified portfolio, and strong cash flow generation, which are traits that compound value over time.